Evidence map›Paper›PMID 25914801›Full record

ArticleIranian journal of pediatric hematology and oncology2015

Low frequency of c-MPL gene mutations in Iranian patients with Philadelphia-negative myeloproliferative disorders.

A Ghotaslou, F Nadali, B Chahardouli, N Alizad Ghandforosh, S H Rostami, K Alimoghaddam, A Ghavamzadeh

Open access · greenAbstract read
In one paragraph

Article in Iranian journal of pediatric hematology and oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

A GhotaslouMS.c Student , Department of Hematology,School of Allied Medical Sciences , Tehran university of Medical Sciences, Tehran , Iran.
F NadaliAssociate Professor, Departement of Hematology, School of Allied Medical Sciences , Tehran university of Medical Sciences , Tehran, Iran.
B ChahardouliAssistant Professor, Hematology-Oncology and Stem cell Transplantation Research Center, Tehran university of Medical Sciences, Tehran, Iran.
N Alizad GhandforoshMS.c Student, Hematology-Oncology and Stem cell Transplantation Research Center, Tehran university of Medical Sciences, Tehran, Iran.
S H RostamiAssistant Professor, Hematology-Oncology and Stem cell Transplantation Research Center, Tehran university of Medical Sciences, Tehran, Iran.
K AlimoghaddamProfessor, Hematology-Oncology and Stem cell Transplantation Research Center, Tehran university of Medical Sciences, Tehran, Iran.
A GhavamzadehProfessor, Hematology-Oncology and Stem cell Transplantation Research Center, Tehran university of Medical Sciences, Tehran, Iran.
Stem Cell Technology Research Center · IRIran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMyeloproliferative disorders are a group of diseases characterized by increased proliferation of myeloid lineage. In addition to JAK2V617F mutation, several mutations in the c-MPL gene have been reported in patients with philadelphia-negative chronic myeloproliferative disorders that could be important in the pathogenesis of diseases. The aim of the present study was to investigate the frequency of c-MPL and JAK2V617F mutations in Iranian patients with Philadelphia-negativemyeloproliferative disorders. MATERIAL AND

methodsPeripheral blood samples were collected from 60 patients with Philadelphia-negative MPD) Subgroups ET and PMF) and 25 healthy subjects as control group. The mutation status of c-MPL and Jak2V617F were investigated by using Amplification-refractory mutation system (ARMS) and Allele-Specific PCR (AS-PCR), respectively. The results were confirmed by sequencing.

resultsAmong 60 patients, 34 (56.6%) and 1(1.7%) had Jak2V617F and c-MPL mutation, respectively. Patients with Jak2V617F mutation had higher WBC counts and hemoglobin concentration than those without the mutation (p= 0.005, p=0.003). In addition, for all healthy subjects in control group, mutations were negative.

conclusionsThe present study revealed that the c-MPL mutations unlike the Jak2V617F mutations are rare in Iranian patients with Ph-negative MPNs and the low mutation rate should be considered in the design of screening strategies of MPD patients.

Indexed as

ARMS –PCRc- MPL mutationJAK2V617FMyeloproliferative Disorders

Identifiers

PMID25914801
PMCPMC4402155
OpenAlexW2159542591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.